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1. Background
The initial and subsequent revised upper respiratory 
tract infection (URTI) guideline for South Africa (SA) 
was published in 2004 and in 2008 in the SAMJ and the 
South African Journal of Epidemiology and Infection, 
respectively.[1,2] In 2014, new multidisciplinary experts were invited 
to join the original working group of the Infectious Diseases Society 
of Southern Africa to prepare the current recommendations. The 
methods used are similar to those described before, and the process 
was done electronically, including review from international experts.
There is a worldwide increase in antibiotic resistance, and studies 
suggest that this is contributed to by inappropriate use of antibiotics, 
particularly for URTIs.[3] Viral infections cause the majority of URTIs. 
All clinicians should know the natural history of the ‘common cold’ 
so that a deviation from normal can be managed effectively. Most 
important is an appreciation that clear nasal secretions frequently 
become purulent without signifying secondary bacterial disease, and 
that coughing is a normal accompaniment (Fig. 1).
The organisms responsible for most bacterial URTIs are similar 
in all age groups. Streptococcus pneumoniae (the pneumococcus) 
was previously the most common bacterial cause of acute otitis 
media (AOM) and sinusitis. Haemophilius influenzae has replaced 
pneumococci as the most frequently isolated pathogen following 
routine vaccination of children with pneumococcal conjugate 
vaccines (PCVs) (PCV-7 was introduced in SA in 2009 and replaced 
by PCV-13 in 2011).[4]
Systematic reviews suggest that in high-income countries the benefit 
of antibiotics for acute pharyngotonsillitis, AOM and acute bacterial 
rhinosinusitis (ABRS) is extremely limited.[5-7] For example, 13 (95% 
confidence interval (CI) 9 - 22) adults with ABRS require antibiotics 
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to benefit one.[5] However, there are few data 
from low- and middle-income countries, 
where rheumatic fever and suppurative 
complications such as mastoiditis are more 
common. Through simple recommendations 
of antibiotics with a relatively narrow spectrum, 
patients ought to be well managed, serious 
complications avoided and the propensity 
to select for resistance minimised. The most 
frequently recommended initial antibiotics of 
choice for URTIs therefore remain penicillin 
and amoxicillin.
The recommendations for duration of 
therapy differ: ABRS and acute pharyngo-
tonsillitis should be treated for 5 and 10 days, 
respectively, and AOM for 5 or 7 days. Recent 
evidence suggests that a shorter duration of 
antibiotic treatment is associated with less 
emergence of resistant pathogens.[8] Duration 
will always depend on clinical response, and 
in some patients antibiotic duration may 
need to be shortened or prolonged. However, 
10 days of oral penicillin is required to 
eradicate group A β-haemolytic streptococci 
(GABHS) (S. pyogenes) in patients with 
pharyngotonsillitis.
The recommendations for frequency 
of administration vary according to the 
site of infection and the pharmacokinetic/
pharmacodynamic (PK/PD) profiles of the 
drugs used. In AOM a twice-daily dose of 
amoxicillin has the same clinical efficacy as 
amoxicillin administered three times a day. For 
optimal clinical success, the antibiotic dosage 
must be tailored to the individual. A common 
cause of treatment failure and antibiotic 
resistance is suboptimal dosing. For example, 
in AOM 5 mL is erroneously prescribed as a 
standard dose for a child weighing 5 - 15 kg, 
instead of individualising doses by body mass. 
Dosages in this guideline include both the 
registered standard doses and higher doses, 
which are recommended where high-level 
antibiotic resistance is reported (see Tables 6 
and 7). All paediatric doses are given as mg/
kg per dose, followed by frequency of daily 
administration. Recommendations have been 
made based on surveillance of appropriate 
pathogens and relevant publications.[4,9,10]
For S. pneumoniae, an important patho-
gen causing AOM and ABRS, resistance 
to β-lactam antibiotics can be overcome 
by increasing antibiotic dosage. For exam-
ple, a higher dose of amoxicillin of 90 mg/
kg/d is recommended for AOM and ABRS. 
Amoxicillin should be effective for H. influ-
enzae not producing β-lactamases. Because 
of concerns of high-level macrolide resistance 
among isolates of S. pneumoniae in some areas 
of practice in SA, this class is reserved for 
patients with severe β-lactam antibiotic allergy. 
Furthermore, in terms of PK/PDs and clinical 
studies that include microbiological efficacy 
results, all macrolides, including azithromycin, 
are ineffective in eradicating H. influenzae.
Recommendations for initial antibiotics 
of choice as well as alternative choices of 
antibiotics are given. The first-line antibiotics 
penicillin or amoxicillin remain the agents 
of choice. The indications for alternative 
antibiotics may include the following:
• Allergy or intolerance to first-line agents
• Recent prior use of first-line agents
• Complicated and/or severe initial 
presentation
• High-risk cases likely or known to be 
infected with highly resistant organisms
• Failed initial therapy.
These recommendations are based on best 
practice, taking into account unique local 
circumstances.
 2. Acute 
pharyngotonsillitis
Acute pharyngotonsillitis is an inflam matory 
condition of the pharyngeal wall, often divided 
into pharyngitis and tonsillitis. Respiratory 
viruses, including adenoviruses, Coxsackie 
Nasal stuness
and throat irritation
Low-grade fever,
malaise, myalgia
Sneezing and watery
nasal discharge Coughing in 60 - 80%
of cases (does not imply
bacterial disease)
Persists up to 10 days
in 35% of casesMucopurulent
secretions 1 - 3 days
later
Persists up to 10 days
in 31% of cases
and/or and/or
Fig. 1. Natural history of the common cold.
Table 1. Diagnostic and treatment criteria for acute pharyngotonsillitis
1.  Symptoms suggestive of acute pharyngitis/tonsillitis are sore throat, fever, difficulty in swallowing, halitosis, etc. However, clinicians’ ability to 
differentiate GABHS pharyngitis from other causes is limited. Therefore:
2.  The prescence of coryza, cough, conjunctivitis, hoarseness, anterior stomatitis, discrete ulcerative lesions or diarrhoea makes GABHS unlikely, 
and no antibiotics are recommended.
3. If none of the above symptoms is present, two alternative approaches are recommended:
• A throat swab for GABHS: if positive, prescribe antibiotics*
• No throat swab for GABHS: empiric antibiotic therapy for patients aged 3 - 21 years†
4. Tender anterior cervical lymphadenopathy, pharyngeal erythema or exudate increases the likelihood of GABHS pharyngitis.
*A delay in antibiotic prescription pending availability of culture results does not reduce efficacy in ARF prevention.
†Throat swabs for GABHS confirmation may be not be feasible in many SA settings owing to increased direct and indirect financial expenditure and additional healthcare visits.
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A virus, influenza virus, parainfluenza virus 
and Epstein-Barr virus (EBV), are the major 
cause of pharyngitis. Bacteria, especially 
GABHS (S. pyogenes), account for 5 - 30% of 
cases.[11] Correctly performed throat culture 
has a sensitivity of 90 - 95% for detecting 
GABHS. Non-infectious causes of pharyngitis 
include allergy and exposure to irritating 
substances. Most cases of viral and bacterial 
acute pharyngitis are self-limiting, including 
those caused by GABHS, so the primary 
reason for considering antibiotic therapy is 
to prevent acute rheumatic fever (ARF). Of 
note, as approximately two-thirds of patients 
with ARF have no preceding sore throat, 
antibiotics have only a limited ability to reduce 
the incidence of ARF. Patients with rheumatic 
heart disease or prior episode(s) of ARF should 
receive secondary penicillin prophylaxis, but 
require antibiotic therapy for acute pharyngitis 
(suggestive of GABHS) initially (Table 1).
2.1 Antibiotic recommendations for 
streptococcal pharyngotonsillitis
The treatment of choice is penicillin (Table 2).
2.1.1 Penicillin
Penicillin reduces the risk of ARF and 
provides some symptom relief in GABHS.[12] 
A single dose of intramuscular benzathine 
penicillin is adequate, but oral therapy may 
be preferred if compliance is considered 
likely. The mixture of benzathine penicillin 
and procaine penicillin gives a less painful 
injection.[13] Alternatively, a dilution of 
benzathine penicillin with 1% lidocaine has 
been shown to be well tolerated.[14] When 
given by mouth, penicillin can be given twice 
or three times daily instead of four times a day. 
Penicillin should be given 30 minutes before a 
meal, as food reduces its absorption. A 10-day 
course is recommended. An important point 
in favour of continued use of penicillin is the 
lack of resistance by GABHS, as opposed to 
the use of erythromycin and other macrolides, 
where widespread use promotes resistance.[15,16] 
An additional advantage of penicillin is its 
narrow spectrum of activity, which reduces 
the risk of selection of resistance.
2.1.2 Amoxicillin
Amoxicillin is an alternative to penicillin VK 
and has the advantage of no food restrictions 
(Table 3). However, a rash can occur when 
pharyngotonsillitis is caused by EBV infection, 
which can lead to an erroneous diagnosis 
of penicillin allergy or, rarely, a severe skin 
reaction. However, recent evidence suggests 
that this rash is much less common with 
amoxicillin (~30% risk in confirmed EBV 
infection) than with ampicillin. Several trials 
have demonstrated non-inferiority of once-
daily amoxicillin to twice-daily amoxicillin 
or penicillin V.[17,18] Once-daily regimens may 
improve patient adherence.
2.1.3 Alternative antibiotic choices
2.1.3.1 Short-course therapy (5 days)
Short-course therapy with several antibiotics 
including the cephalo sporins (cefuroxime, 
cefprozil, cefpodoxime) has been shown to be 
non-inferior to a 10-day course of penicillin 
VK.[6] However, whether shorter courses 
provided similar reduction in ARF is unknown. 
Furthermore, cephalosporins are broader-
spectrum agents than penicillin/amoxicillin 
and have a greater propensity to select for 
resistance. A 10-day course of penicillin or 
amoxicillin is therefore recommended.
2.1.3.2 Antibiotics for β-lactam allergy
Macrolide/azalide resistance in GABHS is a 
major concern, and use of these agents should 
therefore be restricted to penicillin-allergic 
patients (Table 4).
2.2 Symptom relief
The mainstay of the management of acute 
pharyngitis is symptom atic. This includes 
adequate analgesia and antipyretics for the 
relief of fever-related symptoms (generally 
paracetamol or ibuprofen), and sufficient 
hydration.
3. Acute otitis media
AOM is a common childhood illness – 75% 
of children have at least one episode by 3 
Table 2. Penicillin recommendations for acute pharyngotonsillitis
Children
Penicillin VK, 250 mg twice daily for 10 days (<27 kg) or 500 mg twice daily for 10 days (>27 kg) (given 30 minutes before food)
Benzathine penicillin (intramuscular injection)
3 - 5 years: 600 000 U
>5 years: 1.2 MU*
Adolescents and adults
Penicillin VK, 500 mg twice daily for 10 days (given 30 minutes before food)
Benzathine penicillin (intramuscular injection) 1.2 MU*
*1.2 MU as a single dose. To minimise the discomfort of parenteral administration, the medication should be given at room temperature. For patients receiving 1.2 million U, 300 000 U can be 
given as procaine penicillin. Alternatively, dilute benzathine penicillin with 1% lidocaine.
Table 3. Amoxicillin recommendations for acute pharyngotonsillitis
Children*
Amoxicillin 50 mg/kg/d once daily (maximum 1 000 mg) for 10 days
Adolescents and adults* 
 Amoxicillin 500 - 1 000 mg twice daily (alternatively, 50 mg/kg/d once daily (maximum 
3 000 mg)) for 10 days
*Dose to the closest increment of 125 mg.
Table 4. Recommendations for β-lactam allergy in acute pharyngotonsillitis
Children
Azithromycin 10 - 20 mg/kg/d once daily for 5 days
Clarithromycin 15 mg/kg/d, divided into two doses, for 10 days
Adolescents and adults
Azithromycin 500 mg once daily for 3 days
Clarithromycin 500 mg twice daily or 500 mg modified-release once daily for 10 days
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years of age. However, AOM is often misdiagnosed (Table 5). The 
main bacterial causes of AOM are S. pneumoniae, non-typeable H. 
influenzae, and Moraxella catarrhalis. Since the introduction in RSA 
of PCV-7 in 2009, followed by PCV-13 in 2011, the relative frequency 
of these three major middle ear pathogens has changed. H. influenzae 
has replaced S. pneumoniae as the most frequently isolated middle 
ear pathogen.[4] Up to 12.2% (range 9.5 - 15.5%) of H. influenzae 
isolated from respiratory tract infections in SA produce β-lactamase, 
and this is even more frequent if the child was recently on antibiotics, 
resulting in resistance to penicillins.[10] As otitis media may be part of 
neonatal sepsis, any neonate with AOM and fever requires evaluation 
for sepsis. Causative organisms in neonatal AOM include coliforms, 
group B β-haemolytic streptococci and Staphylococcus aureus.
3.1 Treatment of AOM
As AOM is often viral in aetiology, with even bacterial AOM 
frequently resolving spontaneously, antibiotics may be deferred for 
48 hours while symptomatic therapy is administered, except for AOM 
cases associated with a bulging tympanum and a temperature of 
>38°C, where, although this is controversial, immediate treatment is 
recommended. In addition, if symptoms persist or worsen, antibiotics 
should be started. A useful approach is to provide a prescription 
to be filled only if no improvement by 48 hours; this approach is 
reasonable where good follow-up is possible in children ≥2 years 
of age. However, in patients with limited access to healthcare and 
because of the risks of a serious infection with S. pneumoniae and/
or H. influenzae, we recommend that treatment commence from the 
first visit, provided the AOM is correctly diagnosed.
Antibiotics should be considered especially in the following cases:
• Recurrent AOM
• Immunocompromised patients
• Neonates
• Structural ENT or immunological abnormalities
• Fever (temperature >38°C) or pain >48 hours
• Day-care attendees or siblings of children attending day-care 
centres.
Risk factors for resistant S. pneumoniae infections include age (≤2 
years), attendance at day-care centres or siblings of children attending 
day-care centres, not vaccinated with PCVs, prior AOM within the past 
6 months, and antibiotic treatment within the past 3 months. These 
influence the choice and dosage of antibiotics. Risk factors for resistant 
H. influenzae infections have not been elucidated, but a recent course 
of antibiotics that are not resistant to β-lactamases (i.e. amoxicillin) 
increases the risk for β-lactamase-producing H. influenzae.
Paracetamol (10 - 15 mg/kg 4 - 6-hourly) or ibuprofen (5 - 10 mg/
kg 8-hourly) can be given for symptom relief (avoid under- and 
overdosing). Although decongestants are widely prescribed for 
rhinitis, their use in AOM is controversial and generally discouraged. 
If used, topical nasal application for a maximum of 3 days is 
preferable.
3.2 AOM with tympanostomy tubes (AOMT)
AOM with otorrhoea in patients with tympanostomy tubes is 
considered a separate clinical entity, since in a child with glue 
ear a biofilm disease is present, so acute otitis in this situation 
represents acute exacerbation of a chronic process. This is a common 
problem, and culture of otorrhoea fluid will often show significant 
growth of bacteria such as Pseudomonas aeruginosa and S. aureus 
in addition to the usual pathogens. As β-lactams do not cover 
the entire spectrum of organisms cultured, a topical otological 
formulation of ciprofloxacin is an efficacious therapeutic option 
for managing AOMT, avoiding oral treatment.[19] The advantages 
of topical antibiotics administered correctly, rather than systemic 
antibiotics, include significantly higher tissue levels, substantially 
reduced adverse effects and, perhaps most importantly, considerably 
less likelihood of antimicrobial resistance.
3.3 Antibiotic choices for AOM
The initial antibiotic treatment of choice, except in neonates, is 
amoxicillin. Amoxicillin-clavulanate is recommended as the initial 
antibiotic treatment of choice for suspected resistant H. influenzae, 
particularly if there is history of prior antibiotic use (preceding 
30 days) with an antibiotic that was not β-lactamase stable (e.g 
amoxicillin), or if local data show a high proportion (≥15%) of 
resistance to amoxicillin (mediated by β-lactamase production).
3.3.1 Amoxicillin
The recommended dosage of amoxicillin is 80 - 90 mg/kg/d. This 
higher dose is associated with a better eradication of H. influenzae and 
Table 5. Diagnostic criteria for AOM
1.  AOM is defined as an acute upper respiratory tract infection, affecting one or both ears (often associated with infection in the rest of the upper 
respiratory tract), presenting with:
• Otalgia (holding, tugging, rubbing of the ear in a non-verbal child)
• Hearing loss
• Pyrexia, with nausea and dizziness that may develop concurrently
2.  Symptom presentation varies with age. However, as typical symptoms overlap with other conditions, a clinical history alone is not sufficient 
to predict whether AOM is present. The middle ear mucositis develops an effusion, in this case suppuration, as evidenced by a tympanic 
membrane that may become:
• Red
• Oedematous
• Immobile
• Bulging
3.  Hence, to confirm the diagnosis, middle ear effusion and inflammation of the eardrum have to be identified by visualisation of the tympanic 
membrane (TM). Signs of these are fullness, bulging, cloudiness and redness of the TM. Pneumotoscopy and tympanometry are very useful in 
determining the presence of a middle ear effusion. Other causes of a ‘red’ TM include crying, otitis externa, myringitis and barotrauma. AOM is 
as a consequence frequently misdiagnosed. Similarly, over-diagnosis is common.
349       May 2015, Vol. 105, No. 5
FORUM
overcomes high-level penicillin-resistant pneumococci, particularly 
prevalent for:
• Age ≤2 years
• Day-care attendees or siblings of children attending day-care 
centres
• AOM in previous 6 months
• Antibiotic administration during 30 days preceding the AOM 
episode.
3.3.2 Amoxicillin-clavulanate
The addition of a β-lactamase inhibitor (clavulanate) extends the spec-
trum of amoxicillin to include β-lactamase-producing H. influenzae and 
M. catarrhalis. A high-dose amoxicillin-clavulanate preparation (90 mg/
kg amoxicillin and a constant amount of clavulanate of 6.4 mg/kg) is 
available in a paediatric formulation. This gives dosages adequate to also 
eradicate S. pneumoniae that are susceptible to or have high-level resis-
tance to penicillin. This formulation may not be available in all SA sec-
tors. In order to achieve the higher dose, additional amoxicillin can be 
added to standard-dose amoxicillin-clavulanate formulations to achieve 
an amoxicillin concentration of 80 - 90 mg/kg, which is better than sim-
ply doubling the doses of standard preparations (additional clavulanate 
is not required, and maintaining the clavulanate dose lowers the risk 
of gastrointestinal side-effects). Similarly, if the high-dose amoxicillin-
clavulanate formulation (2 000 mg amoxicillin-125 mg clavulanate) that 
is registered for adults is not available, additional amoxicillin (1 000 mg) 
can be added to a standard-dose amoxicillin-clavulanate formulation 
(e.g. 875 mg amoxicillin-125 mg clavulanate).
3.3.3 Oral cephalosporins
Cefuroxime axetil and cefpodoxime are the only oral cephalo-
sporins that give middle ear fluid (MEF) levels sufficiently above 
the minimum inhibitory concentration (MIC) for both penicillin-
sensitive and some intermediate-resistant S. pneumoniae and for 
H. influenzae.[20] Considering the high prevalence of β-lactam 
resistance in many areas of SA, these cephalosporins should 
be prescribed at the higher dosages detailed below if used to 
treat AOM. Based upon PK/PD findings and clinical trials of 
AOM, cefuroxime axetil and cefpodoxime are expected to fail in 
many cases of penicillin-intermediate and resistant pneumococcal 
strains, while cefprozil (15 mg/kg twice daily) should not be 
used empirically in this setting, as it is only effective against 
penicillin-susceptible pneumococci.[21] Cefaclor, cefixime and 
loracarbef are less active in vitro against S. pneumoniae and are 
not recommended.
3.3.4 Parenteral cephalosporins
The MEF concentration of ceftriaxone exceeds the MICs for AOM 
pathogens for >50 hours after a single 50 mg/kg intramuscular 
injection. However, a 3-day regimen is clinically superior, 
particularly in non-responsive AOM caused by penicillin-resistant 
S. pneumoniae.[22] Ceftriaxone use should be reserved for failure of 
high-dose amoxicillin-clavulanate, for severe presentations, or if oral 
administration is unreliable. These scenarios may require specialist 
consultation.
3.3.5 Macrolides/azalides
The erm gene mutation causing high-level resistance to macrolides, 
which cannot be overcome by dose increase, has been identified in 
the majority of erythromycin-resistant S. pneumoniae strains in some 
sectors in SA.[23] Macrolides are therefore not recommended for routine 
empirical antibiotic therapy of S. pneumoniae infections and are reserved 
for type 1 β-lactam hypersensitivity. Furthermore, in terms of PK/PDs 
Table 6. Antibiotic recommendations for children with AOM or ABRS
Initial antibiotic treatment Failure of initial antibiotic treatment after 48 - 72 hours
Recommended drug of choice
 Amoxicillin (80 - 90 mg/kg/d 
divided into 2 doses)
<2 years 7 days
>2 years 5 days
OR
 Amoxicillin-clavulanate* (90 
mg/kg/d amoxicillin-6.4 mg/
kg/d clavulanate divided into 
2 doses)
 Cefuroxime† (30 mg/kg/d 
divided into 2 doses)
 Cefpodoxime† (16 mg/kg/d 
divided into 2 doses)
<2 years 7 days
>2 years 5 days
Alternative treatment if penicillin 
allergy (non-type 1)
 Azithromycin (10 mg/kg once 
daily) for 3 days
 Clarithromycin (15 - 30 mg/
kg/d divided into 2 doses) for 
5 days
 Erythromycin estolate (40 mg/
kg/d divided into 4 doses) for 
5 days
Alternative treatment if penicillin 
allergy (type 1)
 Levofloxacin‡ (20 mg/kg/d 
once daily or divided into 2 
doses) for 5 days
Recommended drug of choice
Amoxicillin-clavulanate* 
 (90 mg/kg/d amoxicillin-6.4 
mg/kg/d clavulanate divided 
into 2 doses)
<2 years 7 - 10 days
> 2years 5 - 7 days
OR
 Ceftriaxone§ (50 mg/kg/d IM 
or IV once daily) for 3 days 
Alternative treatment 
 Ceftriaxone§ (50 mg/kg/d IM 
or IV once daily) for 3 days
 Clindamycin (90 - 150 
mg/kg/d divided into 3 
doses) with or without a 
second- or third-generation 
cephalosporin† for 5 - 7 days 
Failure of antibiotic therapy, 
severe toxicity and/or 
progression beyond the  
middle ear
 Refer for further evaluation 
and management
 
IM = intramuscular; IV = intravenous.
*If the high-dose amoxicillin-clavulanate formulation (90 mg/kg/d amoxicillin-6.4 mg/kg/d clavulanate) is not available, standard-dose amoxicillin-clavulanate (e.g. 45 mg/kg/d amoxicillin-6.4 mg/
kg/d clavulanate divided into 2 doses) plus additional amoxicillin (40 - 45 mg/kg/d divided into 2 doses) can be used. Amoxicillin-clavulanate may be considered first-line therapy in patients with:
• Recent amoxicillin therapy (previous 30 days)
• Concurrent conjunctivitis[7]
• Complicated initial presentations, e.g. periorbital oedema in cases of ABRS
• Suspected resistant H. influenzae pending local epidemiology (% β-lactamase production)
• Additional risk factors for AOM caused by β-lactamase-producing pathogens may include immunocompromised patients and/or neonates.
†Cephalosporins are alternative β-lactamase-stable agents available for the treatment of AOM. The higher dosages of cephalosporins recommended would cover for most pneumococcal 
isolates of intermediate resistance to penicillin, but not necessarily for pneumococcal isolates with high-level resistance. The particular choice of cephalosporins would depend on physician 
or patient preference, availability and cost. The cephalosporins (second or third generation) may also be used as alternative treatment for non-type 1 β-lactam allergies (refer to section 5, 
β-lactam allergy).
‡For children with a complicated and/or severe initial presentation and a history of immediate type 1 hypersensitivity response to penicillin, levofloxacin is recommended as an alternative to 
amoxicillin-clavulanate or ceftriaxone (refer to section 5, β-lactam allergy). Confirmed β-lactam type 1 hypersensitivity (positive skin test) is the only scenario in which levofloxacin in URTIs in 
children is recommended.
§Ceftriaxone may also be used as first-line therapy in complicated initial presentations, e.g. periorbital oedema in cases of ABRS, preferably in consultation with an otorhinolaryngologist.
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and clinical studies with microbiological results, all macrolides, including 
azithromycin, are not effective in eradication of H. influenzae.
3.3.6 Trimethoprim-sulfamethoxazole (TMP-SMX)
The high rate of resistance of S. pneumoniae and H. influenzae in SA 
precludes using TMP-SMX. High bacteriological failure rates have 
been noted in double-tap studies.[24]
3.4 Duration of therapy for AOM
Most antibiotics are clinically effective for uncomplicated AOM 
in regimens of 5 days, since eradication of organisms takes place 
within 72 hours.[25] However, therapy beyond 72 hours is required for 
adequate eradication of potentially pathogenic bacteria colonising the 
nasopharynx, which otherwise predispose to relapses of AOM. Further 
studies are needed to determine the optimal duration of therapy in 
children <2 years of age or with non-responsive AOM.[20,26] Until then, 
therapy for 7 days is recommended for AOM in the following groups:
• Age ≤2 years
• Recurrent or chronic AOM
• Complicated AOM.
3.5 Failure to respond to antibiotics in AOM
For clinical failure (e.g. persistent fever) after 48 - 72 hours of 
appropriate, compliant initial antibiotic therapy, consider referral to 
an otorhinolaryngologist for tympanocentesis and MEF culture. This 
is relevant in areas with a high prevalence of antibiotic-resistant S. 
pneumoniae, as are the majority of major urban centres in SA.
3.6 Antibiotic recommendations for AOM
3.6.1 Children 
Antibiotic recommendations for children are set out in Table 6.
3.6.2 Adults
For adults, AOM and ABRS have identical treatment (Table 7).
3.7 Antibiotic recommendations for AOMT
The recommended topical formulation contains ciprofloxacin 0.3% and 
dexamethasone 0.1% in an otic suspension, applied four drops twice 
daily for 7 days. The technique of application of the drops is essential to 
the success of this treatment regimen. Aural toilet by suctioning must be 
performed before instilling the drops into the external auditory canal, 
and must be followed by tragal pressure to push the drops through the 
tympanostomy tubes into the middle ear. A disposable nasal aspirator 
may be used for suctioning at home.
4. Acute bacterial rhinosinusitis
ABRS is usually preceded by a viral URTI. Allergy, trauma, dental 
infection or other factors leading to inflammation of the nose and 
paranasal sinuses may also predispose individuals to ABRS. The 
most common bacterial isolates from the maxillary sinuses in ABRS 
are similar to AOM, namely S. pneumoniae, H. influenzae and M. 
catarrhalis. However, both the prevalence of H. influenzae and the 
proportion of β-lactamase-producing H. influenzae have markedly 
increased in URTIs, including ABRS in children and adults, since the 
widespread use of PCV. The diagnostic criteria for ABRS are set out 
in Table 8.
Antibiotic therapy must be capable of eradicating S. pneumoniae, 
which, as in AOM, causes most of the serious sequelae. Other 
streptococci, anaerobic bacteria and S. aureus occur in a small 
percentage of cases. Chlamydophila pneumoniae and other ‘atypical’ 
pathogens should be considered in patients with chronic sinusitis. 
Fungi are rarely associated with sinusitis and may be seen in allergic 
sinusitis and immunocompromised hosts. However, their clinical 
Table 7. Antibiotic recommendations for adults with ABRS or AOM
Initial antibiotic treatment Failure of initial antibiotic treatment after 48 - 72 hours
Recommended drug of choice
 Amoxicillin (1 g 8-hourly) for 
5 days
OR
 Amoxicillin-clavulanate* 
(2 000 mg amoxicillin- 125 mg 
clavulanate 12-hourly) for  
5 days
 Cefuroxime† (1 000 mg 
12-hourly) for 5 days
 Cefpodoxime† (400 mg 
12-hourly) for 5 days
Alternative treatment if penicillin 
allergy
 Telithromycin (800 mg once 
daily) for 5 days
 Gemifloxacin (320 mg once 
daily) for 5 days
 Levofloxacin (500 mg 
12-hourly or 750 mg once 
daily) for 5 days
 Moxifloxacin (400 mg once 
daily) for 5 days
Recommended drug of choice
 Amoxicillin-clavulanate* 
(2 000 mg amoxicillin-125 
mg clavulanate 12-hourly) for 
5 - 7 days
 Telithromycin (800 mg once 
daily) for 5 - 7 days
 Gemifloxacin (320 mg once 
daily) for 5 - 7 days
 Levofloxacin (500 mg 
12-hourly or 750 mg once 
daily) for 5 - 7 days
 Moxifloxacin (400 mg once 
daily) for 5 - 7 days
 Clindamycin‡ (450 mg 
8-hourly) for 5 - 7 days
 Ceftriaxone§ for 3 days (IV/IM)
Failure of antibiotics, severe 
toxicity and/or progression 
outside of the sinuses
 Refer to otorhinolaryngologist 
for further evaluation and 
management 
IV = intravenous; IM = intramuscular.
*If the high-dose amoxicillin-clavulanate formulation (2 000 mg amoxicillin-125 mg clavulanate) is not available, the standard-dose amoxicillin-clavulanate formulation (875 mg amoxicillin-125 mg 
clavulanate 12-hourly) plus additional amoxicillin (1 000 mg 12-hourly) can be used. Amoxicillin-clavulanate may be considered first-line therapy in patients with:
• Recent amoxicillin therapy (previous 30 days)
• Recurrent ABRS
• Suspected resistant H. influenzae pending local epidemiology (% β-lactamase production)
• Additional risk factors for ABRS caused by β-lactamase-producing pathogens may include immunocompromised patients, including pregnant patients and diabetics.
†The higher dosages of cephalosporins recommended would cover for most pneumococcal isolates of intermediate resistance to penicillin, but not necessarily for pneumococcal isolates with high-
level resistance. The particular choice of cephalosporins would depend on physician or patient preference, availability and cost. The cephalosporins (second or third generation) may also be used as 
alternative treatment for non-type 1 β-lactam allergies (refer to section 5, β-lactam allergy).
‡Clindamycin use is restricted to confirmed pneumococcal ABRS unresponsive to β-lactam antibiotics or as additional therapy to provide for anaerobic and S. aureus cover, despite the lack of 
clinical evidence at this time of the safety or efficacy of combination therapy for ABRS.
§Ceftriaxone or the respiratory fluoroquinolones may also be used as first-line therapy in complicated initial presentations, e.g. periorbital oedema, preferably in consultation with an 
otorhinolaryngologist.
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significance in immune-competent patients 
is unclear.
Multiple factors play a role in antibiotic 
selection for ABRS. S. pneumoniae may be 
associated with serious intracranial and 
extrasinus complications, and hence requires 
adequate coverage in initial therapy. Cover for 
H. influenzae (and M. catarrhalis in children) 
should be considered. Prior antibiotic use 
is a major risk factor for antibiotic-resistant 
strains. Because recent antibiotic exposure 
increases the risk of carriage and infection 
with resistant organisms, the choice and 
dosage of antibiotic therapy must take into 
account a history of recent antibiotic use. 
Other factors to consider are the severity of 
disease, its rate of progression, and varying 
rates of resistance in SA. Regarding whether 
antibiotics are necessary for ABRS, recent 
meta-analyses of antibiotics v. placebo 
showed only marginal benefit.[5] Overall, 13 
(95% CI 9 - 22) adults require antibiotics to 
benefit one patient.
4.1 Duration of antibiotic treatment 
for ABRS
The duration of antibiotic treatment 
for ABRS is classically 10 days, based 
on published clinical trials in which 
pre- and post-treatment sinus aspirates 
were performed. However, evidence for 
moxifloxacin and telithromycin suggests 
that a shorter course of 5 - 7 days is clinically 
and/or bacteriologically equivalent to a 
10-day course. Recent adult studies also 
show that bacteriological eradication occurs 
within 72 hours with moxifloxacin (400 mg 
once daily) or with high-dose, short-course 
levofloxacin (750 mg once daily for 5 days). 
This higher dose of levofloxacin improves its 
PK/PD profile, and in a comparative trial of 
this dose v. levofloxacin 500 mg once daily 
for 10 days, clinical and microbiological 
efficacy was similar.
A recent meta-analysis examined the effi-
cacy and safety of short v. longer courses of 
antibiotic therapy for adults with ABRS in 
12 randomised controlled trials (RCTs).[5] No 
statistical difference in efficacy was noted 
between short-course (3 - 7 days) v. long-
course (6 - 10 days) antibiotic therapy (odds 
ratio (OR) 0.95; 95% CI  0.81 - 1.12). In 
addition, no differences in microbiologi-
cal efficacy (OR  1.30; 95% CI 0.62 - 2.74), 
relapse rates (OR 0.95; 95% CI 0.63 - 1.37) or 
adverse effects (OR 0.88; 95% CI 0.71 - 1.09) 
were found. However, if only the studies that 
compared 5 days (short course) v. 10 days 
(long course) were included (five RCTs), 
adverse effects were significantly fewer for 
short-course treatment (OR 0.79; 95% CI 
0.63 - 0.98). Data for children are inconclu-
sive, however, as shorter courses of therapy 
have not been studied. The recommended 
duration of therapy for uncomplicated ABRS 
in adults is therefore 5 days.
4.2 Failure to respond to antibiotics 
in ABRS
For clinical failure (e.g. persistent fever) 
after 48 - 72 hours of appropriate, compliant 
antibiotic therapy, consider referral to an 
otorhinolaryngologist for further evaluation. 
A computed tomography scan, fibreoptic 
endoscopy or sinus aspiration and culture 
may be necessary. This is relevant in areas 
with high prevalence of antibiotic-resistant 
S. pneumoniae, as are most major urban 
centres in SA.
4.3 Antibiotic recommendations  
for ABRS
4.3.1 Children
Antibiotic recommendations for children 
with AOM or ABRS are set out in Table 6.
4.3.2 Adults
Antibiotic recommendations for adults with 
ABRS or AOM are set out in Table 7.
5. Beta-lactam allergy
The high prevalence of penicillin non-
susceptibility and cross-resistance in S. 
pneumoniae has complicated the management 
of penicillin-allergic patients and limited the 
choice of alternative agents, particularly in 
children. Clinicians should differentiate an 
immediate type 1 IgE-mediated hypersensitivity 
reaction from other less dangerous types 
of hypersensitivity. Classic signs of type 1 
hypersensitivity are anaphylaxis, angio-
oedema, urticarial rash and bronchospasm. If 
a type I hypersensitivity reaction to penicillin 
has occurred, all β-lactam antibiotics should 
be avoided unless there is no alternative drug 
available, when penicillin desensitisation can 
be attempted as an inpatient.
Patients with other types of hypersensitivity 
reactions, usually a maculopapular rash 
on amoxicillin, should avoid all penicillins 
but may tolerate other β-lactam antibiotics 
such as cephalosporins. The first-generation 
cephalosporins should be avoided as they have 
a higher risk of cross-reactivity with penicillin, 
but this risk is much lower for second- or third-
generation cephalosporins (reported to be only 
0.1%).[27,28]
Consensus opinion suggests that if 
the previous reaction to penicillin was a 
maculopapular rash, it is relatively safe to use 
second- or third-generation cephalosporins, 
and use would depend on the patient’s 
social circumstances and access to follow-
up. However, in patients with a remote 
history of a rash on penicillin, it is often 
difficult to differentiate a maculopapular 
rash from an urticarial rash – all β-lactam 
antibiotics should be avoided if urticaria 
occurred on penicillins, as this is a type 1 
reaction. In this setting, skin testing before 
using a cephalosporin is recommended, as a 
positive reaction to penicillin indicates type 
1 hypersensitivity.[5]
In the latter patients, including children 
with a complicated and/or severe initial 
presentation and a history/confirmation of 
immediate type 1 hypersensitivity response 
to penicillin, levofloxacin is recommended 
Table 8. Diagnostic criteria for ABRS
1.  Rhinosinusitis (all-cause including viral) is diagnosed when the following signs and 
symptoms are present:
One of either:
• Anterior or postnasal discharge 
• Nasal obstruction
With or without:
• Facial pain/pressure 
• Change in sense of smell
2. Acute bacterial rhinosinusitis requiring antibiotics is only diagnosed if:
Symptoms >10 days and <3 months
Severe lasting purulence or fever
Worsening of above symptoms (‘second sickening’) occurs in <10 days
3. Acute viral rhinosinusitis (often associated with the common cold) is diagnosed if:
Symptoms <10 days
Non-severe symptoms
No ‘second sickening’ occurred
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as an alternative to amoxicillin-clavulanate or ceftriaxone. Owing 
to possible selection of resistance among pneumococci and other 
pathogens associated with widespread use, this is the only scenario in 
which levofloxacin in URTIs in children is recommended. Although 
levofloxacin’s safety profile in children has been studied extensively, 
the incidence of musculoskeletal events (arthritis or arthralgia and 
tendinopathy) involving weight-bearing joints was increased in 
levofloxacin-treated children.[5,29-31] Experience with moxifloxacin in 
children is relatively limited.
Endorsement. These recommendations are endorsed by the Infectious 
Diseases Society of Southern Africa, the Southern African Society for 
Paediatric Infectious Diseases and the Federation of Infectious Diseases 
Societies of Southern Africa.
Disclaimer. This statement is published for educational purposes only. 
The recommendations are based on currently available scientific evidence 
together with the consensus opinion of the authors. Adherence to these 
recommendations is voluntary and does not account for individual variation 
among patients; the recommendations are not intended to supplant physician 
judgement with respect to particular patients or special clinical situations. In 
addition, the recommendations do not indicate an exclusive diagnostic work-
up or course of treatment or serve as a standard of medical care.
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